A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
Hemolytic disease of the newborn
Erythroblastosis fetalis is a potentially life-threatening blood disorder in a fetus or newborn infant. This article provides a general overview. For more detailed information see the specific disorder:
Erythroblastosis fetalis develops in an unborn infant when the mother and baby have different blood types. The mother produces substances called antibodies that attack the developing baby's red blood cells.
The most common form of erythroblastosis fetalis is ABO incompatibility, which can vary in severity.
The less common form is called Rh incompatibility, which can cause very severe anemia in the baby.
Symptoms in a newborn baby may include:
Specific tests depend on the type of erythroblastosis, but may include:
After birth, depending on the severity, a transfusion usually needs to be performed.
For specific treatment information, see:
The severity of this condition can vary widely. In some instances, the baby has no symptoms of the disease. In other cases, it can lead to death of the baby before or shortly after birth. It can be treated before birth by intrauterine transfusion.
Complications depend on the specific type of erythroblastosis fetalis.
The most severe form of this disease, Rh incompatibility, can be prevented if the mother takes a medicine called RhoGAM at certain times during and after pregnancy. If you have had a baby with this disease, be sure to talk with your doctor if you plan on having another baby.
Gruslin AM, Moore TR. Erythroblastosis fetalis. In: Martin R, Fanaroff A, Walsh M, eds. Neonatal-Perinatal Medicine. Philadelphia, Pa: Mosby Elsevier; 2006:chap 20.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885